Détection et prévention des complications cardiaques des chimiothérapies anticancéreuses

Archives of Cardiovascular Diseases

Volumn 105, Issue 11, 2012, Pages 593-604

  Monsuez, Jean Jacques ^a,b  

^a Cardiologie   (France)

^b Hopital Rene Muret Bigottini   (France)

Author keywords

Cancer; Cardiac toxicity; Chemotherapy; Detection; Prevention

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMLODIPINE; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DASATINIB; DOCETAXEL; DOXORUBICIN; ENALAPRIL; FLUOROURACIL; IFOSFAMIDE; ILOPROST; IMATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PROBUCOL; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; SILDENAFIL; SUNITINIB; TRASTUZUMAB; TROPONIN; VALSARTAN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CYTOTOXIN; LIPOSOME; NATRIURETIC FACTOR; PROTEIN KINASE INHIBITOR;

ACUTE HEART FAILURE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARDIAC IMAGING; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; COST EFFECTIVENESS ANALYSIS; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; EXPERIMENTAL MODEL; FOLLOW UP; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; QUANTITATIVE ANALYSIS; REVIEW; SCINTIANGIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC DYSFUNCTION; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; BLOOD; CARDIOVASCULAR SYSTEM EXAMINATION; CHEMICALLY INDUCED DISORDER; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION TEST; HEART LEFT VENTRICLE FUNCTION; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CYTOTOXINS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HEART DISEASES; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDES; NEOPLASMS; PROTEIN KINASE INHIBITORS; TROPONIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84869498269     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.04.008     Document Type: Review

References (97)

1. T. Force Introduction to cardiotoxicity review series Circ Res 106 2010 19 20
2. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
3. G. Youssef, and M. Links The prevention and management of cardiovascular complications of chemotherapy in patients with cancer Am J Cardiovasc Drugs 5 2005 233 243 (Pubitemid 40994266)
4. J.J. Monsuez, J.C. Charniot, and N. Vignat Cardiac side-effects of cancer chemotherapy Int J Cardiol 144 2010 3 15
5. A.M. Tsimberidou, G. Minotti, and D. Cardinale Managing cardiac risk factors in oncology clinical trials Tex Heart Inst J 38 2011 266 267
6. G. Minotti, P. Menna, and E. Salvatorelli Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229 (Pubitemid 38720829)
7. T. Van Dyke p53 and tumor suppression N Engl J Med 356 2007 79 81 (Pubitemid 46041758)
8. D. Lebrecht, B. Setzer, and U.P. Ketelsen Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy Circulation 108 2003 2423 2429 (Pubitemid 37413552)
9. N. Nozaki, T. Shishido, and Y. Takeishi Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice Circulation 110 2004 2869 2874 (Pubitemid 39473611)
10. A. De Angelis, E. Piegari, and D. Cappetta Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function Circulation 121 2010 276 292
11. C. Huang, X. Zhang, and J.M. Ramil Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice Circulation 121 2010 675 683
12. L. Wojnowski, B. Kulle, and M. Schirmer NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity Circulation 112 2005 3754 3762 (Pubitemid 43739516)
13. P.G. Horan, M.F. McMullin, and P.P. McKeown Anthracycline cardiotoxicity Eur Heart J 27 2006 1137 1138
14. M.F. Stoddard, J. Seeger, and N.E. Liddell Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans J Am Coll Cardiol 20 1992 62 69
15. M.R. Bristow, J.W. Mason, and M.E. Billingham Dose-effect and structure-function relationships in doxorubicin cardiomyopathy Am Heart J 102 1981 709 718 (Pubitemid 11030031)
16. S.E. Lipshultz, S.D. Colan, and R.D. Gelber Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 324 1991 808 815
17. E. Tan-Chiu, G. Yothers, and E. Romond Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 2005 7811 7819 (Pubitemid 46657378)
18. M.H. Chen, R. Kerkela, and T. Force Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 2008 84 95
19. T.M. Suter, M. Procter, and D.J. van Veldhuisen Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial J Clin Oncol 25 2007 3859 3865 (Pubitemid 47477261)
20. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
21. A. Seidman, C. Hudis, and M.K. Pierri Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221 (Pubitemid 34177427)
22. M.S. Ewer, M.T. Vooletich, and J.B. Durand Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 2005 7820 7826 (Pubitemid 46657379)
23. M.S. Ewer, and S.M. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2005 2900 2902 (Pubitemid 46224107)
24. T.K. Choueiri, E.L. Mayer, and Y. Je Congestive heart failure risk in patients with breast cancer treated with bevacizumab J Clin Oncol 29 2011 632 638
25. R. Kerkela, L. Grazette, and R. Yacobi Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916 (Pubitemid 44175142)
26. K. Strebhardt, and A. Ullrich Another look at imatinib mesylate N Engl J Med 355 2006 2481 2482 (Pubitemid 44903754)
27. G. Rosti, G. Martinelli, and M. Baccarani In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' Nat Med 13 2007 15 [author reply 15-6] (Pubitemid 46067371)
28. J.C. Trent, S.S. Patel, and J. Zhang Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate Cancer 116 2010 184 192
29. P.J. Perik, B. Rikhof, and F.A. de Jong Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity Ann Oncol 19 2008 359 361 (Pubitemid 351201720)
30. Z.R. Estabragh, K. Knight, and S.J. Watmough A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib Leuk Res 35 2011 49 51
31. G. Turrisi, F. Montagnani, and S. Grotti Congestive heart failure during imatinib mesylate treatment Int J Cardiol 145 2010 148 150
32. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
33. T.F. Chu, M.A. Rupnick, and R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019 (Pubitemid 350236338)
34. A.Y. Khakoo, C.M. Kassiotis, and N. Tannir Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor Cancer 112 2008 2500 2508
35. E.A. Perez, M. Koehler, and J. Byrne Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 2008 679 686 (Pubitemid 351810568)
36. J. Voortman, and G. Giaccone Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report BMC Cancer 6 2006 129
37. O. Enrico, B. Gabriele, and C. Nadia Unexpected cardiotoxicity in haematological bortezomib treated patients Br J Haematol 138 2007 396 397 (Pubitemid 47035391)
38. D. Nowis, M. Maczewski, and U. Mackiewicz Cardiotoxicity of the anticancer therapeutic agent bortezomib Am J Pathol 176 2010 2658 2668
39. M. de Forni, M.C. Malet-Martino, and P. Jaillais Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study J Clin Oncol 10 1992 1795 1801 (Pubitemid 23059959)
40. S. Coughlin, S. Das, and J. Lee Capecitabine induced vasospastic angina Int J Cardiol 130 2008 e34 e36
41. M. Ng, D. Cunningham, and A.R. Norman The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) Eur J Cancer 41 2005 1542 1546 (Pubitemid 40981835)
42. E.K. Rowinsky, W.P. McGuire, and T. Guarnieri Cardiac disturbances during the administration of taxol J Clin Oncol 9 1991 1704 1712
43. P. Westervelt, R.A. Brown, and D.R. Adkins Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide Blood 98 2001 266 271
44. L.F. de Geus-Oei, A.M. Mavinkurve-Groothuis, and L. Bellersen Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity J Nucl Med 52 2011 560 571
45. R.G. Schwartz, W.B. McKenzie, and J. Alexander Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography Am J Med 82 1987 1109 1118
46. S. Wakasugi, A.J. Fischman, and J.W. Babich Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy J Nucl Med 34 1993 1283 1286
47. K. Saito, K. Takeda, and S. Okamoto Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method J Nucl Cardiol 7 2000 553 561 (Pubitemid 32042441)
48. M.A. de Korte, E.G. de Vries, and M.N. Lub-de Hooge 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity Eur J Cancer 43 2007 2046 2051
49. B.H. Lee, L.S. Goodenday, and G.J. Muswick Alterations in left ventricular diastolic function with doxorubicin therapy J Am Coll Cardiol 9 1987 184 188 (Pubitemid 17219564)
50. J. Banchs, J.L. Jefferies, and J.C. Plana Imaging for cardiotoxicity in cancer patients Tex Heart Inst J 38 2011 268 269
51. M. Civelli, D. Cardinale, and A. Martinoni Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity Int J Cardiol 111 2006 120 126 (Pubitemid 44107547)
52. J. Walker, N. Bhullar, and N. Fallah-Rad Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging J Clin Oncol 28 2010 3429 3436
53. S. Tassan-Mangina, D. Codorean, and M. Metivier Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr 7 2006 141 146 (Pubitemid 43257199)
54. J.M. Appel, P. Sogaard, and C.E. Mortensen Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer J Am Soc Echocardiogr 24 2011 200 206
55. G. Mantovani, C. Madeddu, and C. Cadeddu Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers Oncologist 13 2008 1296 1305
56. G. Mercuro, C. Cadeddu, and A. Piras Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers Oncologist 12 2007 1124 1133 (Pubitemid 350007024)
57. J. Ganame, P. Claus, and B. Eyskens Acute cardiac functional and morphological changes after Anthracycline infusions in children Am J Cardiol 99 2007 974 977 (Pubitemid 46483288)
58. J.L. Hare, J.K. Brown, and R. Leano Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab Am Heart J 158 2009 294 301
59. E. Ho, A. Brown, and P. Barrett Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study Heart 96 2010 701 707
60. H. Sawaya, I.A. Sebag, and J.C. Plana Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
61. E. Piegari, G. Di Salvo, and B. Castaldi Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model Ultrasound Med Biol 34 2008 370 378 (Pubitemid 351625438)
62. K. Oberholzer, R.P. Kunz, and M. Dittrich Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer Rofo 176 2004 1245 1250 (Pubitemid 39237183)
63. N. Fallah-Rad, M. Lytwyn, and T. Fang Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 2008 5
64. J.C. Lightfoot, R.B. D'Agostino Jr., and C.A. Hamilton Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model Circ Cardiovasc Imaging 3 2010 550 558
65. G. Daugaard, U. Lassen, and P. Bie Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction Eur J Heart Fail 7 2005 87 93 (Pubitemid 40092497)
66. I. Germanakis, M. Kalmanti, and F. Parthenakis Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines Int J Cardiol 108 2006 212 215 (Pubitemid 43330616)
67. A. Kouloubinis, L. Kaklamanis, and N. Ziras ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy Int J Cardiol 122 2007 195 201 (Pubitemid 47615179)
68. M.T. Sandri, M. Salvatici, and D. Cardinale N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction Clin Chem 51 2005 1405 1410 (Pubitemid 41060872)
69. E. Gimeno, M. Gomez, and J.R. Gonzalez NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma Leuk Res 35 2011 715 720
70. J.J. Monsuez Cardiac biomarkers beyond heart disease Leuk Res 35 2011 703 704
71. D. Cardinale, M.T. Sandri, and A. Martinoni Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy J Am Coll Cardiol 36 2000 517 522
72. D. Cardinale, M.T. Sandri, and A. Colombo Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754 (Pubitemid 38737923)
73. D. Cardinale, A. Colombo, and R. Torrisi Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
74. D. Heintel, C. Skrabs, and A. Hauswirth Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age Ann Hematol 89 2010 163 169
75. H. Wildiers, R. Jurcut, and J. Ganame A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients Crit Rev Oncol Hematol 67 2008 133 138 (Pubitemid 351902234)
76. R. Jurcut, H. Wildiers, and J. Ganame Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer J Am Soc Echocardiogr 21 2008 1283 1289
77. M. Lotrionte, G. Palazzoni, and R. Natali Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study Int J Cardiol 135 2009 72 77
78. R.S. Cvetkovic, and L.J. Scott Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy Drugs 65 2005 1005 1024 (Pubitemid 40667518)
79. F. Testore, S. Milanese, and M. Ceste Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience Am J Cardiovasc Drugs 8 2008 257 263
80. S.E. Lipshultz, N. Rifai, and V.M. Dalton The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 351 2004 145 153 (Pubitemid 38886649)
81. L. Elbl, H. Hrstkova, and I. Tomaskova Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients Eur J Pediatr 164 2005 678 684 (Pubitemid 41476493)
82. C.K. Tebbi, W.B. London, and D. Friedman Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease J Clin Oncol 25 2007 493 500 (Pubitemid 350002954)
83. W.L. Salzer, M. Devidas, and W.L. Carroll Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group Leukemia 24 2010 355 370
84. N. Siveski-Iliskovic, M. Hill, and D.A. Chow Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect Circulation 91 1995 10 15
85. S. Yamanaka, T. Tatsumi, and J. Shiraishi Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes J Am Coll Cardiol 41 2003 870 878 (Pubitemid 36308399)
86. D. Outomuro, D.R. Grana, and F. Azzato Adriamycin-induced myocardial toxicity: new solutions for an old problem Int J Cardiol 117 2007 6 15 (Pubitemid 46399979)
87. T.G. Neilan, D.S. Jassal, and M.F. Scully Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression Eur Heart J 27 2006 1251 1256
88. P.W. Fisher, F. Salloum, and A. Das Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity Circulation 111 2005 1601 1610 (Pubitemid 40525159)
89. N. Kalay, E. Basar, and I. Ozdogru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262 (Pubitemid 44855419)
90. D. Cardinale, A. Colombo, and M.T. Sandri Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
91. H. Nakamae, K. Tsumura, and Y. Terada Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498 (Pubitemid 41691573)
92. M. Martin, F.J. Esteva, and E. Alba Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations Oncologist 14 2009 1 11
93. A.L. Jones, M. Barlow, and P.J. Barrett-Lee Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
94. D. Slamon, W. Eiermann, and N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
95. J.R. Walker, A. Sharma, and M. Lytwyn The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity J Am Soc Echocardiogr 24 2011 699 705
96. C. Vaklavas, D. Lenihan, and R. Kurzrock Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target Oncologist 15 2010 130 141
97. O. Mir, R. Coriat, and S. Ropert Treatment of bevacizumab-induced hypertension by amlodipine Invest New Drugs 30 2012 702 707